Recognized expertise in bioseparations, plasma-derived therapeutics and drug development. Prometic provides non-exclusive license to its proprietary technology for the purification of protein therapies as well as viral inactivation and prion removal. Prometic is developing plasma-derived protein therapies for orphan indications as well as small-molecule therapeutics targeting fibrosis and autoimmune diseases. R&D facilities are located in the UK, Canada and USA; manufacturing in multiple locations globally.